// App-Quantinova.ai

S138 : EFFECT OF OLUTASIDENIB (FT-2102) ON COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MUTANT IDH1 ACUTE MYELOID LEUKEMIA. RESULTS FROM A PLANNED INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL

Researchers

Presenter

  • Stphane de Botton

Principal Investigators

  • Recher Christian

  • Andrew Wei

  • Pau Montesinos

  • David Taussig

  • Arnaud Pigneux

  • Thorsten Braun

  • Antonio Curti

  • Jordi Esteve

  • Carolyn Grove

  • Brian A. Jonas

  • Asim Khwaja

  • Ollivier Legrand

  • Pierre Peterlin

  • Montserrat Arnan Sangerman

  • William G. Blum

  • Daniela Cilloni

  • Devendra K. Hiwase

  • Joseph G. Jurcic

  • Jrgen Krauter

  • Xavier Thomas

  • Justin M. Watts

  • Jay Yang

  • Olga Polyanskaya

  • Julie Brevard

  • Jennifer Sweeney

  • Patrick Henrick

  • Hesham Mohamed

  • Jorge Cortes

  • Pierre Fenaux

Medical Centers

  • The Alfred Hospital, Melbourne, Australia

  • Instituto Catalan de Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain

  • Centre Hospitalier Universitaire (CHU) de Bordeaux, Université de Bordeaux,Bordeaux,France

  • Institut Gustave-Roussy, Villejuif, France

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • IUCT-Oncopole, CHU de Toulouse,Toulouse,France

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italy

  • Karmanos Cancer Institute Detroit MI United States

  • University of Turin, Turin, Italy

  • Royal Adelaide Hospital and SA Pathology,Adelaide,Australia

  • Georgia Cancer Center at Augusta University,Agusta ,United States

  • University of California, Davis School of Medicine, Sacramento, CA

  • CHU de Nantes, Service d'hématologie Clinique,Nantes,France

  • Hopital Saint Antoine and Universite Pierre et Marie Curie, Paris, France

  • Kings College London, London, United Kingdom

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • PathWest &amp

  • Service d'Hematologie Seniors/Hopital Saint-Louis, Universite Paris 7, Paris, France

  • FORMA Therapeutics, Inc.,Watertown,United States

  • Pediatric Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain

  • Columbia University, New York, New York, United States

  • Braunschweig Municipal Hospital,Braunschweig,Germany

  • Avicenne Hospital Paris XIII University,Bobigny,France

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Hospices Civils de Lyon, Lyon-Sud Hospital,Lyon,France

  • The Royal Marsden Hospital, London, United Kingdom

  • Hematology and Medical Oncology,University of Miami, Sylvester Comprehensive Cancer Center ,Miami,États-unis

Locations

  • Australia

  • Spain

  • France

  • United States

  • Italy

  • United Kingdom

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • FT-2102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02719574

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved